{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:55:16Z","timestamp":1793044516386,"version":"4.5.0"},"reference-count":205,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Treating posterior segment and retinal diseases poses challenges due to the complex structures in the eye that act as robust barriers, limiting medication delivery and bioavailability. This necessitates frequent dosing, typically via eye drops or intravitreal injections, to manage diseases, often leading to side effects with long-term use. Suprachoroidal injection is a novel approach for targeted drug delivery to the posterior segment. The suprachoroidal space is the region between the sclera and the choroid and provides a potential route for minimally invasive medication delivery. Through a more targeted delivery to the posterior segment, this method offers advantages over other routes of administration, such as higher drug concentrations, increased bioavailability, and prolonged duration of action. Additionally, this approach minimizes the risk of corticosteroid-related adverse events such as cataracts and intraocular pressure elevation via compartmentalization. This review focuses on preclinical and clinical studies published between 2019 and 2023, highlighting the potential of suprachoroidal injection in treating a variety of posterior segment diseases. However, to fully harness its potential, more research is needed to address current challenges and limitations, such as the need for technological advancements, refinement of injection techniques, and consideration of cost and accessibility factors. Future studies exploring its use in conjunction with biotech products, gene therapies, and cell-based therapies can lead to personalized treatments that can revolutionize the field of ophthalmology.<\/jats:p>","DOI":"10.3390\/ph16091241","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:19:39Z","timestamp":1693556379000},"page":"1241","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Suprachoroidal Injection: A Novel Approach for Targeted Drug Delivery"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-6900","authenticated-orcid":false,"given":"Kevin Y.","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie K.","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Gholamian","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Zaharia","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Ophthalmology, University of Sherbrooke, Sherbrooke, QC J1G 2E8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5594-359X","authenticated-orcid":false,"given":"Simon D.","family":"Tran","sequence":"additional","affiliation":[{"name":"Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Joly-Chevrier, M., Akbar, D., and Tran, S.D. (2023). Overcoming Treatment Challenges in Posterior Segment Diseases with Biodegradable Nano-Based Drug Delivery Systems. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041094"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1517\/17425247.3.2.275","article-title":"Ocular Drug Delivery","volume":"3","author":"Ghate","year":"2006","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal Drug Delivery to the Back of the Eye Using Hollow Microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3928\/23258160-20180831-07","article-title":"Suprachoroidal Space Alterations Following Delivery of Triamcinolone Acetonide: Post-Hoc Analysis of the Phase 1\/2 HULK Study of Patients with Diabetic Macular Edema","volume":"49","author":"Lampen","year":"2018","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.jval.2022.07.008","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide Injectable Suspension for the Treatment of Macular Edema Associated with Uveitis in the United States: A Cost-Effectiveness Analysis","volume":"25","author":"Bhattacharyya","year":"2022","journal-title":"Value Health"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Dubashynskaya, N., Poshina, D., Raik, S., Urtti, A., and Skorik, Y.A. (2019). Polysaccharides in Ocular Drug Delivery. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12010022"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Naftali Ben Haim, L., and Moisseiev, E. (2021). Drug Delivery via the Suprachoroidal Space for the Treatment of Retinal Diseases. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13070967"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ajo.2008.12.008","article-title":"A Pilot Study of Enhanced Depth Imaging Optical Coherence Tomography of the Choroid in Normal Eyes","volume":"147","author":"Margolis","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","unstructured":"Mahabadi, N., and Al Khalili, Y. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_10","unstructured":"Niederkorn, J.Y., and Kaplan, H.J. (2007). Chemical Immunology and Allergy, KARGER."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Vurgese, S., Panda-Jonas, S., and Jonas, J.B. (2012). Scleral Thickness in Human Eyes. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0029692"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted Administration into the Suprachoroidal Space Using a Microneedle for Drug Delivery to the Posterior Segment of the Eye","volume":"53","author":"Patel","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.37765\/ajmc.2022.89270","article-title":"Microinjection via the Suprachoroidal Space: A Review of a Novel Mode of Administration","volume":"28","author":"Ciulla","year":"2022","journal-title":"Am. J. Manag. Care"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000317072","article-title":"Axial Length of Myopia: A Review of Current Research","volume":"225","author":"Meng","year":"2011","journal-title":"Ophthalmologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.preteyeres.2016.12.001","article-title":"Pharmacokinetic Aspects of Retinal Drug Delivery","volume":"57","author":"Heikkinen","year":"2017","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_16","first-page":"233","article-title":"Hydrostatic Pressure of the Suprachoroidal Space","volume":"30","author":"Emi","year":"1989","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1034\/j.1600-0420.1998.760502.x","article-title":"Light Microscopy of Uveoscleral Drainage Routes after Gelatine Injections into the Suprachoroidal Space","volume":"76","author":"Krohn","year":"1998","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0420.1997.tb00245.x","article-title":"Corrosion Casts of the Suprachoroidal Space and Uveoscleral Drainage Routes in the Human Eye","volume":"75","author":"Krohn","year":"1997","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.exer.2016.03.008","article-title":"Circumferential Flow of Particles in the Suprachoroidal Space Is Impeded by the Posterior Ciliary Arteries","volume":"145","author":"Chiang","year":"2016","journal-title":"Exp. Eye Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and Obstacles of Ocular Pharmacokinetics and Drug Delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Wu, K.Y., Ashkar, S., Jain, S., Marchand, M., and Tran, S.D. (2023). Breaking Barriers in Eye Treatment: Polymeric Nano-Based Drug-Delivery System for Anterior Segment Diseases and Glaucoma. Polymers, 15.","DOI":"10.3390\/polym15061373"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular Complications of Topical, Peri-Ocular, and Systemic Corticosteroids","volume":"11","author":"Carnahan","year":"2000","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tyagi, P., Kadam, R.S., and Kompella, U.B. (2012). Comparison of Suprachoroidal Drug Delivery with Subconjunctival and Intravitreal Routes Using Noninvasive Fluorophotometry. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0048188"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and Subretinal Injections of AAV Using Transscleral Microneedles for Retinal Gene Delivery in Nonhuman Primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A Comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/aos.14861","article-title":"Aqueous Eye Drops Containing Drug\/Cyclodextrin Nanoparticles Deliver Therapeutic Drug Concentrations to Both Anterior and Posterior Segment","volume":"100","author":"Loftsson","year":"2022","journal-title":"Acta Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Uchino, M., Yokoi, N., Shimazaki, J., Hori, Y., Tsubota, K., and on behalf of the Japan Dry Eye Society (2022). Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based Survey. J. Clin. Med., 11.","DOI":"10.3390\/jcm11020367"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e044987","DOI":"10.1136\/bmjopen-2020-044987","article-title":"Prevalence and Predictors of Medication Non-Adherence among People Living with Multimorbidity: A Systematic Review and Meta-Analysis","volume":"11","author":"Foley","year":"2021","journal-title":"BMJ Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14740338.6.1.45","article-title":"The Side Effects of the Prostaglandin Analogues","volume":"6","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1124\/jpet.107.131656","article-title":"Studies with an Orally Bioavailable Alpha V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats","volume":"324","author":"Santulli","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.bmc.2006.04.013","article-title":"Exploration of Orally Available Calpain Inhibitors. Part 3: Dipeptidyl Alpha-Ketoamide Derivatives Containing Pyridine Moiety","volume":"14","author":"Shirasaki","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/bjo.2004.050054","article-title":"Penetration of Moxifloxacin into the Human Aqueous Humour after Oral Administration","volume":"89","author":"Kampougeris","year":"2005","journal-title":"Br. J. Ophthalmol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1177\/112067210701700316","article-title":"Aqueous and Vitreous Penetration of Levofloxacin after Topical and\/or Oral Administration","volume":"17","author":"Sakamoto","year":"2007","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1002\/jps.21200","article-title":"Molecular Design for Enhancement of Ocular Penetration","volume":"97","author":"Shirasaki","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(02)00438-6","article-title":"Acetazolamide: Future Perspective in Topical Glaucoma Therapeutics","volume":"248","author":"Kaur","year":"2002","journal-title":"Int. J. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(03)31001-0","article-title":"Role of Mucins in the Function of the Corneal and Conjunctival Epithelia","volume":"231","author":"Gipson","year":"2003","journal-title":"Int. Rev. Cytol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0169-409X(01)00193-4","article-title":"Transscleral Drug Delivery for Posterior Segment Disease","volume":"52","author":"Geroski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1089\/jop.2007.0117","article-title":"Pharmacokinetic Study of Dexamethasone Disodium Phosphate Using Intravitreal, Subconjunctival, and Intravenous Delivery Routes in Rabbits","volume":"24","author":"Hosseini","year":"2008","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0002-9394(99)00129-4","article-title":"High Concentration of Dexamethasone in Aqueous and Vitreous after Subconjunctival Injection","volume":"128","author":"Weijtens","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s11095-007-9408-z","article-title":"Drug Elimination Kinetics Following Subconjunctival Injection Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging","volume":"25","author":"Kim","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of Cornea, Sclera, and Conjunctiva: A Literature Analysis for Drug Delivery to the Eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40264-015-0273-0","article-title":"Comparative Safety and Tolerability of Anti-VEGF Therapy in Age-Related Macular Degeneration","volume":"38","author":"Modi","year":"2015","journal-title":"Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0300060518816884","article-title":"Intravitreal Fluocinolone Acetonide Implant (ILUVIEN\u00ae) for Diabetic Macular Oedema: A Literature Review","volume":"47","author":"Massa","year":"2019","journal-title":"J. Int. Med. Res."},{"key":"ref_44","first-page":"870987","article-title":"Strategy for the Management of Macular Edema in Retinal Vein Occlusion: The European VitreoRetinal Society Macular Edema Study","volume":"2015","author":"Adelman","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40662-021-00261-3","article-title":"Intravitreal Corticosteroids for Diabetic Macular Edema: A Network Meta-Analysis of Randomized Controlled Trials","volume":"8","author":"Gao","year":"2021","journal-title":"Eye Vis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"780","DOI":"10.3928\/23258160-20170928-01","article-title":"Treatment Burden in Neovascular AMD:Visual Acuity Outcomes Are Associated with Anti-VEGF Injection Frequency","volume":"48","author":"Hussain","year":"2017","journal-title":"Ophthalmic Surg. Lasers Imaging Retina"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Macular Oedema Due to Retinal Vein Occlusion: A Real-World Analysis of 15 613 Patient Eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00006982-200507000-00002","article-title":"Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes","volume":"25","author":"Chin","year":"2005","journal-title":"Retina"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Multicenter Uveitis Steroid Treatment Trial Research Group (2010). The Multicenter Uveitis Steroid Treatment (MUST) Trial: Rationale, Design and Baseline Characteristics. Am. J. Ophthalmol., 149, 550\u2013561.e10.","DOI":"10.1016\/j.ajo.2009.11.019"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group (2017). Association between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs. Systemic Anti-Inflammatory Therapy and Visual Acuity at 7 Years Among Patients with Intermediate, Posterior, or Panuveitis. JAMA, 317, 1993\u20132005.","DOI":"10.1001\/jama.2017.5103"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, Durability, and Safety of Intravitreal Faricimab up to Every 16 Weeks for Neovascular Age-Related Macular Degeneration (TENAYA and LUCERNE): Two Randomised, Double-Masked, Phase 3, Non-Inferiority Trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"ref_54","unstructured":"(2023, July 06). Genentech: Press Releases|Friday, 28 January 2022. Available online: https:\/\/www.gene.com\/media\/press-releases\/14943\/2022-01-28\/fda-approves-genentechs-vabysmo-the-firs."},{"key":"ref_55","unstructured":"(2023, July 06). Genentech: Press Releases|Friday, 22 October 2021. Available online: https:\/\/www.gene.com\/media\/press-releases\/14935\/2021-10-22\/fda-approves-genentechs-susvimo-a-first-."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1023\/A:1023238530504","article-title":"Vitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers","volume":"20","author":"Ruponen","year":"2003","journal-title":"Pharm. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1167\/iovs.05-0165","article-title":"Vitreous: A Barrier to Nonviral Ocular Gene Therapy","volume":"46","author":"Peeters","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner Limiting Membrane Barriers to AAV-Mediated Retinal Transduction from the Vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal Delivery of Viral and Nonviral Gene Therapy for Retinal Diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and Safety of Voretigene Neparvovec (AAV2-HRPE65v2) in Patients with RPE65-Mediated Inherited Retinal Dystrophy: A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","article-title":"Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years","volume":"128","author":"Maguire","year":"2021","journal-title":"Ophthalmology"},{"key":"ref_62","unstructured":"(2023, July 06). REGENXBIO Announces Additional Positive Interim Phase I\/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD|Regenxbio Inc. Available online: https:\/\/ir.regenxbio.com\/news-releases\/news-release-details\/regenxbio-announces-additional-positive-interim-phase-iiia-and\/."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.drudis.2019.03.027","article-title":"Targeting Drug Delivery within the Suprachoroidal Space","volume":"24","author":"Jung","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of Suprachoroidal Drug Delivery: From Benchtop to Clinical Investigation in Ocular Therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Peden, M.C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S.L., Levine, M., Hauswirth, W.W., Ratnakaram, R., and Dawson, W. (2011). Ab-Externo AAV-Mediated Gene Delivery to the Suprachoroidal Space Using a 250 Micron Flexible Microcatheter. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017140"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1021\/mp300716t","article-title":"Light Activated, In Situ Forming Gel for Sustained Suprachoroidal Delivery of Bevacizumab","volume":"10","author":"Tyagi","year":"2013","journal-title":"Mol. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jconrel.2015.02.021","article-title":"Safety and Pharmacodynamics of Suprachoroidal Injection of Triamcinolone Acetonide as a Controlled Ocular Drug Release Model","volume":"203","author":"Chen","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jconrel.2022.05.061","article-title":"Suprachoroidal Delivery Enables Targeting, Localization and Durability of Small Molecule Suspensions","volume":"349","author":"Kansara","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.37765\/ajmc.2023.89324","article-title":"Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Noninfectious Uveitis: An In-Depth Look at Efficacy and Safety","volume":"29","author":"Yeh","year":"2023","journal-title":"Am. J. Manag. Care"},{"key":"ref_70","unstructured":"Fisher, N., Yoo, J., Hancock, S.E., and Andino, R.V. (2018). A Novel Technique to Characterize Key Fluid Mechanic Properties of the SC Injection Procedure in an In Vivo Model, Clear Association for Research in Vision and Ophthalmology Annual Meeting."},{"key":"ref_71","first-page":"24","article-title":"Suprachoroidal Delivery with the SCS Microinjector\u2122: Characterization of Operational Forces","volume":"61","author":"Fisher","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2147\/OPTH.S89784","article-title":"The Suprachoroidal Space: From Potential Space to a Space with Potential","volume":"10","author":"Moisseiev","year":"2016","journal-title":"Clin. Ophthalmol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1167\/iovs.15-16597","article-title":"Real-Time Monitoring of Suprachoroidal Space (SCS) Following SCS Injection Using Ultra-High Resolution Optical Coherence Tomography in Guinea Pig Eyes","volume":"56","author":"Gu","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_74","first-page":"3615","article-title":"Ocular Distribution and Efficacy after Suprachoroidal Injection of AU-011 for Treatment of Ocular Melanoma","volume":"61","author":"Savinainen","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1167\/iovs.16-20377","article-title":"Thickness and Closure Kinetics of the Suprachoroidal Space Following Microneedle Injection of Liquid Formulations","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"107824","DOI":"10.1016\/j.exer.2019.107824","article-title":"Collagenase Injection into the Suprachoroidal Space of the Eye to Expand Drug Delivery Coverage and Increase Posterior Drug Targeting","volume":"189","author":"Jung","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_77","first-page":"320","article-title":"Distribution of Aqueous Solutions Injected Suprachoroidally (SC) in Rabbits","volume":"61","author":"Nork","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/eye.2010.47","article-title":"Prospective Randomized Comparison of DisCoVisc and Healon5 in Phacoemulsification and Intraocular Lens Implantation","volume":"24","author":"Oshika","year":"2010","journal-title":"Eye"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejpb.2015.05.020","article-title":"Formulation to Target Delivery to the Ciliary Body and Choroid via the Suprachoroidal Space of the Eye Using Microneedles","volume":"95","author":"Kim","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jconrel.2022.10.036","article-title":"Six-Month Sustained Delivery of Anti-VEGF from in-Situ Forming Hydrogel in the Suprachoroidal Space","volume":"352","author":"Jung","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1167\/iovs.16-20679","article-title":"Clearance Kinetics and Clearance Routes of Molecules From the Suprachoroidal Space After Microneedle Injection","volume":"58","author":"Chiang","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/ma00054a017","article-title":"Dye Diffusion in Isotropic and Liquid-Crystalline Aqueous (Hydroxypropyl)Cellulose","volume":"26","author":"Mustafa","year":"1993","journal-title":"Macromolecules"},{"key":"ref_83","unstructured":"(2023, May 30). FITC-Dextran Fluorescein Isothiocyanate Dextran. Available online: https:\/\/www.semanticscholar.org\/paper\/FITC-Dextran-Fluorescein-isothiocyanate-dextran\/01c8e9539524bc604f6b45a6bbb06dd03507d82f."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"119935","DOI":"10.1016\/j.biomaterials.2020.119935","article-title":"Sustained Delivery of Acriflavine from the Suprachoroidal Space Provides Long Term Suppression of Choroidal Neovascularization","volume":"243","author":"Hackett","year":"2020","journal-title":"Biomaterials"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/aic.690440123","article-title":"Fiber Matrix Model of Sclera and Corneal Stroma for Drug Delivery to the Eye","volume":"44","author":"Edwards","year":"1998","journal-title":"AIChE J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1167\/iovs.17-23758","article-title":"Targeted Drug Delivery in the Suprachoroidal Space by Swollen Hydrogel Pushing","volume":"59","author":"Jung","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2018.03.001","article-title":"Ocular Drug Delivery Targeted by Iontophoresis in the Suprachoroidal Space Using a Microneedle","volume":"277","author":"Jung","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1038\/mt.2011.304","article-title":"Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina without Detaching the Retina","volume":"20","author":"Touchard","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_89","first-page":"5259","article-title":"Intraocular Distribution and Targeting of Triamcinolone Acetonide Suspension Administered Into the Suprachoroidal Space","volume":"55","author":"Edelhauser","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_90","first-page":"459","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide Suspension: Ocular Pharmacokinetics and Distribution in Rabbits Demonstrates High and Durable Levels in the Chorioretina","volume":"38","author":"Muya","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_91","first-page":"3694","article-title":"Ocular Pharmacokinetics and Safety of Suprachoroidal A01017, Small Molecule Complement Inhibitor, Injectable Suspension in Rabbits","volume":"61","author":"Hancock","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_92","first-page":"3977","article-title":"Suprachoroidal CLS-AX (Axitinib Injectable Suspension), as a Potential Long-Acting Therapy for Neovascular Age-Related Macular Degeneration (NAMD)","volume":"61","author":"Kaiser","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/bjophthalmol-2020-318019","article-title":"Suprachoroidal CLS-TA for Non-Infectious Uveitis: An Open-Label, Safety Trial (AZALEA)","volume":"106","author":"Henry","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.ophtha.2020.01.006","article-title":"Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial","volume":"127","author":"Yeh","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_95","first-page":"3206-A0432","article-title":"Suprachoroidal Triamcinolone Acetonide Injectable Suspension for Macular Edema Associated with Uveitis: Visual and Anatomic Outcomes by Age","volume":"63","author":"Henry","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Merrill, P.T., Henry, C.R., Nguyen, Q.D., Reddy, A., Kapik, B., and Ciulla, T.A. (2021). Suprachoroidal CLS-TA with and without Systemic Corticosteroid and\/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial. Ocul. Immunol. Inflamm., 1\u20138.","DOI":"10.1080\/09273948.2021.1954199"},{"key":"ref_97","first-page":"1139","article-title":"Extension Study of the Safety and Efficacy of CLS-TA for Treatment of Macular Oedema Associated with Non-Infectious Uveitis (MAGNOLIA)","volume":"106","author":"Khurana","year":"2022","journal-title":"Br. J. Ophthalmol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/IAE.0000000000002279","article-title":"Suprachoroidal injection of triamcinolone acetonide, CLS-TA, for macular edema due to noninfectious uveitis: A Randomized, Phase 2 Study (DOGWOOD)","volume":"39","author":"Yeh","year":"2019","journal-title":"Retina"},{"key":"ref_99","first-page":"e20038","article-title":"Safety and Efficacy of Suprachoroidal Injection of Triamcinolone in Treating Macular Edema Secondary to Noninfectious Uveitis","volume":"13","author":"Hanif","year":"2021","journal-title":"Cureus"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.53350\/pjmhs22165164","article-title":"Visual Outcome after Suprachoroidal Injection of Triamcinolone Acetate in Cystoid Macular Edema of Different Pathology","volume":"16","author":"Munir","year":"2022","journal-title":"Pak. J. Med. Health Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1096105","DOI":"10.3389\/fendo.2023.1096105","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factor, Laser Photocoagulation, or Combined Therapy for Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.oret.2018.03.008","article-title":"Suprachoroidal Triamcinolone Acetonide for Diabetic Macular Edema: The HULK Trial","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.oret.2020.08.007","article-title":"Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study","volume":"5","author":"Barakat","year":"2021","journal-title":"Ophthalmol. Retina"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Fazel, F., Malekahmadi, M., Feizi, A., Oliya, B., Tavakoli, M., and Fazel, M. (2023). Suprachoroidal Injection of Triamcinolone Acetonide plus Intravitreal Bevacizumab in Diabetic Macular Edema: A Randomized Pilot Trial. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-02790-y"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.53350\/pjmhs22166301","article-title":"Comparison of Suprachoroidal Triamcinolone Injection with Intravitreal Bevacizumab Vs Intravitreal Bevacizumab Only in Treatment of Refractory Diabetic Macular Edema","volume":"16","author":"Shahid","year":"2022","journal-title":"Pak. J. Med. Health Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"304","DOI":"10.53350\/pjmhs22166304","article-title":"Comparison of Suprachoroidal Injection of Triamcinolone Acetonide Versus Intravitreal Bevacizumab in Primary Diabetic Macular Odema","volume":"16","author":"Anwar","year":"2022","journal-title":"Pak. J. Med. Health Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/OPTH.S351853","article-title":"Suprachoroidal versus Intravitreal Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema","volume":"16","author":"Zakaria","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Shaikh, K., Ahmed, N., Kazi, U., Zia, A., and Aziz, M.Z. (2023). Comparison between Suprachoroidal Triamcinolone and Intravitreal Triamcinolone Acetonide in Patients of Resistant Diabetic Macular Edema. Pak. J. Ophthalmol., 39.","DOI":"10.36351\/pjo.v39i1.1480"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"03000605221089807","DOI":"10.1177\/03000605221089807","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide Using a Custom-Made Needle to Treat Diabetic Macular Edema Post Pars Plana Vitrectomy: A Case Series","volume":"50","author":"Marashi","year":"2022","journal-title":"J. Int. Med. Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.2147\/OPTH.S391319","article-title":"Effectiveness of Suprachoroidal Injection of Triamcinolone Acetonide in Resistant Diabetic Macular Edema Using a Modified Microneedle","volume":"16","author":"Nawar","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"239","DOI":"10.47391\/JPMA.2239","article-title":"Suprachoroidal Injection of Triamcinolone Acetonide for Management of Resistant Diabetic Macular Oedema","volume":"73","author":"Ateeq","year":"2023","journal-title":"JPMA J. Pak. Med. Assoc."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"400","DOI":"10.53350\/pjmhs20221611400","article-title":"To Determine the Efficacy of Suprachoroidal Triamcinolone Injection for the Treatment of Refractory Diabetic Macular Edema","volume":"16","author":"Chandni","year":"2022","journal-title":"Pak. J. Med. Health Sci."},{"key":"ref_113","first-page":"42","article-title":"Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Cases of Resistant Diabetic Macular Edema","volume":"36","author":"Tayyab","year":"2020","journal-title":"Pak. J. Med. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"324","DOI":"10.53350\/pjmhs2023171324","article-title":"Efficacy and Safety of Suprachoroidal Triamcinolone Acetonide in Cases of Resistant Diabetic Macular Edema","volume":"17","author":"Ahmad","year":"2023","journal-title":"Pak. J. Med. Health Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.54112\/bcsrj.v2023i1.202","article-title":"Efficacy of Suprachoroidal Triamcinolone Acetonide Injection in the Treatment of Resistant Diabetic Macular Edema","volume":"2023","author":"Butt","year":"2023","journal-title":"Biol. Clin. Sci. Res. J."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Tharwat, E., Ahmed, R.E.H., Eltantawy, B., Ezzeldin, E.R., and Elgazzar, A.F. (2022). Suprachoroidal Triamcinolone versus Posterior Subtenon Triamcinolone Either Alone or Formulated in the Management of Diabetic Macular Edema. Int. Ophthalmol.","DOI":"10.21203\/rs.3.rs-1909132\/v1"},{"key":"ref_117","first-page":"1152","article-title":"Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy: The Phase II ALTITUDE\u2122 Study","volume":"63","author":"Dhoot","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40942-023-00449-w","article-title":"Combined Intravitreal Dexamethasone and Bevacizumab Injection for the Treatment of Persistent Diabetic Macular Edema (DexaBe Study): A Phase I Clinical Study","volume":"9","author":"Dalgalarrondo","year":"2023","journal-title":"Int. J. Retina Vitr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.oret.2017.07.013","article-title":"Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study","volume":"2","author":"Campochiaro","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_120","unstructured":"(2023, July 15). Clearside Biomedical\u2019s TANZANITE Extension Study in Patients with Macular Edema Associated with Retinal Vein Occlusion Presented at the 40th Annual Macula Society Meeting|Clearside Biomedical, Inc.-IR Site. Available online: https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedicals-tanzanite-extension-study-patients-macular."},{"key":"ref_121","unstructured":"Clearside Biomedical, Inc. (2021). SAPPHIRE: A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Conjunction with Intravitreal Aflibercept in Subjects with Retinal Vein Occlusion, Clearside Biomedical, Inc."},{"key":"ref_122","unstructured":"Clearside Biomedical, Inc. (2021). A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination with an Intravitreal Anti-VEGF Agent in Subjects with Retinal Vein Occlusion, Clearside Biomedical, Inc."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2147\/OPTH.S361636","article-title":"Modified Microneedle for Suprachoroidal Injection of Triamcinolone Acetonide Combined with Intravitreal Injection of Ranibizumab in Branch Retinal Vein Occlusion Patients","volume":"16","author":"Nawar","year":"2022","journal-title":"Clin. Ophthalmol."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Ali, B.M., Azmeh, A.M., and Alhalabi, N.M. (2023). Suprachoroidal Triamcinolone Acetonide for the Treatment of Macular Edema Associated with Retinal Vein Occlusion: A Pilot Study. BMC Ophthalmol., 23.","DOI":"10.1186\/s12886-023-02808-5"},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Muslim, I., Chaudhry, N., and Javed, R.M.M. (2022). Effect of Supra-Choroidal Triamcinolone Injection on Best-Corrected Visual Acuity and Central Retinal Thickness in Patients with Macular Edema Secondary to Retinal Vein Occlusion. Pak. J. Ophthalmol., 38.","DOI":"10.36351\/pjo.v38i1.1347"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/IAE.0b013e3182278b0e","article-title":"Suprachoroidal drug Infusion for the Treatment of Severe Subfoveal Hard Exudates","volume":"32","author":"Rizzo","year":"2012","journal-title":"Retina"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Abdelshafy, A. (2022). One Year Results for Suprachoroidal Triamcinolone Acetonide Injection in Various Retinal Diseases, Benha University.","DOI":"10.1155\/2022\/7947710"},{"key":"ref_128","first-page":"7947710","article-title":"A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema Due to Epiretinal Membrane","volume":"2022","year":"2022","journal-title":"J. Ophthalmol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.18240\/ijo.2022.12.18","article-title":"A Simple Technique for Suprachoroidal Space Injection of Triamcinolone Acetonide in Treatment of Macular Edema","volume":"15","author":"Zhang","year":"2022","journal-title":"Int. J. Ophthalmol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4103\/ijo.IJO_1464_20","article-title":"Modified Inexpensive Needle for Suprachoroidal Triamcinolone Acetonide Injections in Pseudophakic Cystoid Macular Edema","volume":"69","author":"Oli","year":"2021","journal-title":"Indian J. Ophthalmol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"101254","DOI":"10.1016\/j.ajoc.2021.101254","article-title":"A Manually Made Needle for Treating Pseudophakic Cystoid Macular Edema by Injecting Triamcinolone Acetonide in the Suprachoroidal Space: A Case Report","volume":"25","author":"Marashi","year":"2022","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Abdelshafy, A. (2022). Suprachoroidal Triamcinolone Acetonide Injection in Two Chorioretinal Diseases: One Year Results, Benha University.","DOI":"10.1155\/2022\/7947710"},{"key":"ref_133","first-page":"1931","article-title":"Comparison of Suprachoroidal Delivery via an Ab-Externo Approach with the ITrack Microcatheter versus Vitrectomy and Subretinal Delivery for 3 Different AAV Serotypes for Gene Transfer to the Retina","volume":"53","author":"Martorana","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"S217","DOI":"10.1016\/S1525-0016(16)33352-4","article-title":"544. Comparison of AAV Serotype2 Transduction by Various Delivery Routes to the Mouse Eye","volume":"24","author":"Woodard","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-Vectored Suprachoroidal Gene Transfer Produces Widespread Ocular Transgene Expression","volume":"129","author":"Ding","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_136","first-page":"4490","article-title":"Transgene Expression in RPE and Retina after Suprachoroidal Delivery of AAV Vectors","volume":"61","author":"Ding","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_137","first-page":"2909","article-title":"Suprachoroidally Delivered Non-Viral DNA Nanoparticles Transfect Chorioretinal Cells in Non-Human Primates and Rabbits","volume":"60","author":"Kansara","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host Immune Responses after Suprachoroidal Delivery of AAV8 in Nonhuman Primate Eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/tvst.9.13.21","article-title":"Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium\/Choroid in Rabbits","volume":"9","author":"Kansara","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"eaba1606","DOI":"10.1126\/sciadv.aba1606","article-title":"Suprachoroidal Gene Transfer with Nonviral Nanoparticles","volume":"6","author":"Shen","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"617377","DOI":"10.3389\/fnins.2020.617377","article-title":"Interaction Between Mesenchymal Stem Cells and Retinal Degenerative Microenvironment","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/aos.14042","article-title":"Suprachoroidally Injected Pharmacological Agents for the Treatment of Chorio-Retinal Diseases: A Targeted Approach","volume":"97","author":"Noronha","year":"2019","journal-title":"Acta Ophthalmol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4236\/ojoph.2021.111004","article-title":"Does Stem Cell Implantation Have an Effect on Severity of Retinitis Pigmentosa: Evaluation with a Classification System?","volume":"11","author":"Kahraman","year":"2021","journal-title":"Open J. Ophthalmol."},{"key":"ref_144","first-page":"1","article-title":"Suprachoroidal Umbilical Cord Derived Mesenchymal Stem Cell Implantation for the Treatment of Retinitis Pigmentosa in Pediatric Patients","volume":"5","author":"Oner","year":"2023","journal-title":"Am. J. Stem Cell Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"\u00d6zkan, B. (2023, July 06). Suprachoroidal Spheroidal Mesenchymal Stem Cell Implantation in Retinitis Pigmentosa: Clinical Results of 6 Months Follow-Up, Available online: clinicaltrials.gov.","DOI":"10.1186\/s13287-023-03489-z"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1186\/s13256-021-03162-0","article-title":"Managing Solar Retinopathy with Suprachoroidal Triamcinolone Acetonide Injection in a Young Girl: A Case Report","volume":"15","author":"Marashi","year":"2021","journal-title":"J. Med. Case Rep."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Gohil, R., Crosby-Nwaobi, R., Forbes, A., Burton, B., Hykin, P., and Sivaprasad, S. (2015). Caregiver Burden in Patients Receiving Ranibizumab Therapy for Neovascular Age Related Macular Degeneration. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129361"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/09286586.2016.1193617","article-title":"Burden of Wet Age-Related Macular Degeneration and Its Economic Implications in Singapore in the Year 2030","volume":"23","author":"Saxena","year":"2016","journal-title":"Ophthalmic Epidemiol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ICU.0b013e328338679a","article-title":"Complications of Intravitreal Injections","volume":"21","author":"Sampat","year":"2010","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1111\/aos.14681","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factors, Panretinal Photocoagulation and Combined Treatment for Proliferative Diabetic Retinopathy: A Systematic Review and Network Meta-Analysis","volume":"99","author":"Fallico","year":"2021","journal-title":"Acta Ophthalmol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1167\/iovs.16-21230","article-title":"A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model Using Three Targeted Drugs","volume":"58","author":"Tran","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_152","first-page":"498","article-title":"Pharmacokinetics and Biodistribution of Bevacizumab Following Suprachoroidal Injection into the Rabbit Eye Using a Microneedle","volume":"53","author":"Mansoor","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1167\/iovs.10-6291","article-title":"Pharmacokinetics of Pars Plana Intravitreal Injections versus Microcannula Suprachoroidal Injections of Bevacizumab in a Porcine Model","volume":"52","author":"Olsen","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00109-016-1498-9","article-title":"The HIF-1 Antagonist Acriflavine: Visualization in Retina and Suppression of Ocular Neovascularization","volume":"95","author":"Zeng","year":"2017","journal-title":"J. Mol. Med."},{"key":"ref_155","first-page":"2529","article-title":"Porcine Sclera: Thickness and Surface Area","volume":"43","author":"Olsen","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_156","unstructured":"AbbVie (2023). A Phase 2, Randomized, Dose-Escalation, Ranibizumab-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants with Neovascular Age-Related Macular Degeneration (NAMD) (AAVIATE), AbbVie."},{"key":"ref_157","first-page":"1497","article-title":"Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE\u2122 Study","volume":"63","author":"Khanani","year":"2022","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000336045","article-title":"Safety of Submacular Suprachoroidal Drug Administration via a Microcatheter: Retrospective Analysis of European Treatment Results","volume":"227","author":"Tetz","year":"2012","journal-title":"Ophthalmologica"},{"key":"ref_159","first-page":"3299","article-title":"Suprachoroidal Microinjection of Bevacizumab Is Well Tolerated in Human Patients","volume":"54","author":"Widmann","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_160","first-page":"286","article-title":"Efficacy of Suprachoroidal Aflibercept in a Laser Induced Choroidal Neovascularization Model","volume":"57","author":"Patel","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_161","unstructured":"Kissner, J., Patel, S.R., Prusakiewicz, J.J., Alton, D., Bikzhanova, G., Geisler, L., Burke, B., and Noronha, G. (2016). Pharmacokinetics including Ocular Distribution Characteristics of Suprachoroidally Administered CLS011A in Rabbits Could Be Beneficial for a Wet AMD Therapeutic Candidate, ASSOC Research Vision Ophthalmology Inc."},{"key":"ref_162","unstructured":"Clearside Biomedical, Inc. (2022). OASIS: Open-Label, Dose-Escalation, Phase 1\/2a Study of the Safety and Tolerability of Suprachoroidally Administered CLS-AX Following Intravitreal Anti-VEGF Therapy in Subjects with Neovascular Age-Related Macular Degeneration, Clearside Biomedical, Inc."},{"key":"ref_163","unstructured":"Clearside Biomedical, Inc. (2023). Extension Study to Evaluate the Long-Term Outcomes of Subjects Following CLS-AX Administration for Age-Related Macular Degeneration in the CLS-AX CLS1002-101 Study, Clearside Biomedical, Inc."},{"key":"ref_164","unstructured":"Shanghai BDgene Co., Ltd. (2022). A Safety and Efficacy Study of VEGFA-Targeting Gene Therapy to Treat Refractory Retinal and Choroidal Neovascularization Diseases, Shanghai BDgene Co., Ltd."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/or\/2023\/v18i3385","article-title":"Role of Suprachoroidal Anti-VEGF Injections in Recalcitrant Serous Pigment Epithelium Detachment","volume":"18","author":"Datta","year":"2023","journal-title":"Ophthalmol. Res. Int. J."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.4103\/ijo.IJO_1788_21","article-title":"Safety and Efficacy of Suprachoroidal Triamcinolone Acetonide for the Management of Serous Choroidal Detachment Prior to Rhegmatogenous Retinal Detachment Surgery: A Pilot Study","volume":"70","author":"Kohli","year":"2022","journal-title":"Indian J. Ophthalmol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3482","DOI":"10.1177\/11206721221085420","article-title":"Suprachoroidal Triamcinolone Acetonide Injection: A Novel Therapy for Serous Retinal Detachment Due to Vogt-Koyanagi Harada Disease","volume":"32","author":"Tabl","year":"2022","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_168","first-page":"274","article-title":"Suprachoroidal injection of sodium hyaluronate in the treatment of 12 patients with rhegmatogenous retinal detachment","volume":"6","author":"Gao","year":"2019","journal-title":"Chin. J. Ocul. Fundus Dis."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000265503","article-title":"Suprachoroidal Injection of Sodium Hyaluronate as an \u201cinternal\u201d Buckling Procedure","volume":"19","author":"Mittl","year":"1987","journal-title":"Ophthalmic Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bjo.36.7.385","article-title":"Suprachoroidal Air Injection for Detached Retina","volume":"36","author":"Smith","year":"1952","journal-title":"Br. J. Ophthalmol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1167\/tvst.5.6.14","article-title":"Suprachoroidal Corticosteroid Administration: A Novel Route for Local Treatment of Noninfectious Uveitis","volume":"5","author":"Goldstein","year":"2016","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_172","first-page":"3110","article-title":"Evaluation of Suprachoroidal CLS-TA and Oral Prednisone in a Porcine Model of Uveitis","volume":"56","author":"Noronha","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1167\/iovs.13-11747","article-title":"Treatment of Acute Posterior Uveitis in a Porcine Model by Injection of Triamcinolone Acetonide into the Suprachoroidal Space Using Microneedles","volume":"54","author":"Gilger","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_174","first-page":"2927","article-title":"Evaluation of Suprachoroidal Microinjection of Triamcinolone Acetonide in a Model of Panuveitis in Albino Rabbits","volume":"54","author":"Patel","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/IJG.0b013e31814b990d","article-title":"Barriers to Glaucoma Drug Delivery","volume":"17","author":"Ghate","year":"2008","journal-title":"J. Glaucoma"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0002-9394(01)00834-0","article-title":"Brimonidine 0.2% given Two or Three Times Daily versus Timolol Maleate 0.5% in Primary Open-Angle Glaucoma","volume":"131","author":"Konstas","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in Glaucoma: Objective Measurements of Once-Daily and Adjunctive Medication Use","volume":"144","author":"Robin","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2105\/AJPH.83.5.711","article-title":"Treatment for Glaucoma: Adherence by the Elderly","volume":"83","author":"Gurwitz","year":"1993","journal-title":"Am. J. Public Health"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1167\/iovs.14-14651","article-title":"Targeted Delivery of Antiglaucoma Drugs to the Supraciliary Space Using Microneedles","volume":"55","author":"Kim","year":"2014","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2016.02.041","article-title":"Sustained Reduction of Intraocular Pressure by Supraciliary Delivery of Brimonidine-Loaded Poly(Lactic Acid) Microspheres for the Treatment of Glaucoma","volume":"228","author":"Chiang","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_181","first-page":"1533","article-title":"Evaluation of a Novel Biomaterial in the Suprachoroidal Space of the Rabbit Eye","volume":"43","author":"Einmahl","year":"2002","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2001908","DOI":"10.1002\/advs.202001908","article-title":"Drug-Free, Nonsurgical Reduction of Intraocular Pressure for Four Months after Suprachoroidal Injection of Hyaluronic Acid Hydrogel","volume":"8","author":"Chae","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"213162","DOI":"10.1016\/j.bioadv.2022.213162","article-title":"Suprachoroidal Injection of Polyzwitterion Hydrogel for Treating Glaucoma","volume":"142","author":"Hao","year":"2022","journal-title":"Biomater. Adv."},{"key":"ref_184","first-page":"2861","article-title":"Ocular Distribution and Exposure of AU-011 after Suprachoroidal or Intravitreal Administration in an Orthotopic Rabbit Model of Human Uveal Melanoma","volume":"62","author":"Savinainen","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_185","first-page":"1459","article-title":"Suprachoroidal Injection of Microspheres with Microcatheter in a Rabbit Model of Uveal Melanoma","volume":"52","author":"Kang","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_186","first-page":"4025","article-title":"A Phase 1b\/2 Open-Label Clinical Trial to Evaluate the Safety and Efficacy of AU-011 for the Treatment of Choroidal Melanoma","volume":"61","author":"Mruthyunjaya","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"S934","DOI":"10.1016\/j.annonc.2022.07.968","article-title":"842P A Phase II Trial of AU-011, an Investigational, Virus-like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL\/CM) Using Suprachoroidal Administration","volume":"33","author":"Demirci","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5114\/jcb.2019.87407","article-title":"Complications and Adverse Events of Plaque Brachytherapy for Ocular Melanoma","volume":"11","author":"Peddada","year":"2019","journal-title":"J. Contemp. Brachyther."},{"key":"ref_189","unstructured":"Aura Biosciences (2023). A Phase 2 Open-Label, Ascending Single and Repeat Dose Escalation Trial of Belzupacap Sarotalocan (AU-011) via Suprachoroidal Administration in Subjects with Primary Indeterminate Lesions and Small Choroidal Melanoma, Aura Biosciences."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mehy.2017.08.020","article-title":"Suprachoroidal Injection of Biological Agents May Have a Potential Role in the Prevention of Progression and Complications in High Myopia","volume":"107","author":"Venkatesh","year":"2017","journal-title":"Med. Hypotheses"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","article-title":"Myopia","volume":"379","author":"Morgan","year":"2012","journal-title":"Lancet"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00002018-200225040-00002","article-title":"Topical Nonsteroidal Anti-Inflammatory Drugs for Ophthalmic Use: A Safety Review","volume":"25","author":"Gaynes","year":"2002","journal-title":"Drug Saf."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/tde.10.40","article-title":"Recent Advances in Ophthalmic Drug Delivery","volume":"1","author":"Kompella","year":"2010","journal-title":"Ther. Deliv."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/IAE.0b013e3182576d1d","article-title":"Pharmacokinetic Comparison of Ketorolac after Intracameral, Intravitreal, and Suprachoroidal Administration in Rabbits","volume":"32","author":"Wang","year":"2012","journal-title":"Retina"},{"key":"ref_195","first-page":"2770","article-title":"Suprachoroidal Injection of Ketorolac Tromethamine Does Not Cause Retinal Damage","volume":"7","author":"Liu","year":"2012","journal-title":"Neural Regen. Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3109\/02713683.2011.585734","article-title":"Intravitreal Injection of Commercially Available Ketorolac Tromethamine in Eyes with Diabetic Macular Edema Refractory to Laser Photocoagulation","volume":"36","author":"Maldonado","year":"2011","journal-title":"Curr. Eye Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3928\/01913913-20100920-01","article-title":"Effectiveness of Ketorolac Tromethamine in Prevention of Severe Retinopathy of Prematurity","volume":"48","author":"Giannantonio","year":"2011","journal-title":"J. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3129\/i09-281","article-title":"Use of Intraocular Ketorolac Tromethamine for the Treatment of Chronic Cystoid Macular Edema","volume":"45","author":"Margalit","year":"2010","journal-title":"Can. J. Ophthalmol. J. Can. Ophtalmol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/archophthalmol.2010.69","article-title":"Inhibition of Choroidal Neovascularization by Intravitreal Ketorolac","volume":"128","author":"Kim","year":"2010","journal-title":"Arch. Ophthalmol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ajo.2017.11.020","article-title":"Choroidal Changes after Suprachoroidal Injection of Triamcinolone in Eyes with Macular Edema Secondary to Retinal Vein Occlusion","volume":"186","author":"Willoughby","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"ref_201","first-page":"1177","article-title":"Suprachoroidal Injections of AAV for Retinal Gene Delivery in Mouse","volume":"62","author":"Tian","year":"2021","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/hum.2022.222","article-title":"The Degree of Adeno-Associated Virus-Induced Retinal Inflammation Varies Based on Serotype and Route of Delivery: Intravitreal, Subretinal, or Suprachoroidal","volume":"34","author":"Wiley","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/hum.2020.043","article-title":"Retinal Tropism and Transduction of Adeno-Associated Virus Varies by Serotype and Route of Delivery (Intravitreal, Subretinal, or Suprachoroidal) in Rats","volume":"31","author":"Han","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"47","DOI":"10.15283\/ijsc20025","article-title":"First Year Results of Suprachoroidal Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Degenerative Macular Diseases","volume":"14","author":"Kahraman","year":"2021","journal-title":"Int. J. Stem Cells"},{"key":"ref_205","first-page":"4925","article-title":"Pharmacokinetics and Ocular Tolerability of Suprachoroidal CLS-AX (Axitinib Injectable Suspension) in Rabbits","volume":"61","author":"Muya","year":"2020","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/9\/1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:58Z","timestamp":1760129098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/9\/1241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":205,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["ph16091241"],"URL":"https:\/\/doi.org\/10.3390\/ph16091241","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}